A Randomized, Double-Blind (Sponsor-Open), Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Multiple Doses of TAK-828 in Healthy Subjects

Trial Profile

A Randomized, Double-Blind (Sponsor-Open), Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Multiple Doses of TAK-828 in Healthy Subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs TAK 828 (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions
  • Sponsors Takeda
  • Most Recent Events

    • 20 Feb 2017 Status changed from active, no longer recruiting to discontinued.
    • 03 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 13 Jul 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top